1. US Food and Drug Administration. NDA 22-371. Drug Approval package for Astepro® Nasal Spray. August 31, 2009. 2. Astepro® Prescribing information. Meda Pharmaceuticals Inc; 2018. 3. Data on file. Bayer. MP436 CSR Safety and tolerability. 4. NDA 213872. 5. US Department of Health and Human Services. Pediatric Postmarketing Pharmacovigilance and Drug Utilization Review. November 3, 2016. Accessed October 28, 2021. https://www.fda gov/media/100100/download 6. van Bavel J, Howland WC, Amar NJ, Wheeler W, Sacks H. Efficacy and safety of azelastine 0.15% nasal spray administered once daily in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2009;30(5):512-518. doi:10.2500/aap.2009.30.3284. 7. Astelin. Prescribing information. Meda Pharmaceuticals Inc; 2014.